Insolubility Insight
February 26, 2016
1 min read

February 26, 2016
1 min read
February 26, 2016
1 min read
February 26, 2016
1 min read
February 26, 2016
1 min read
February 26, 2016
As medicine makers strive to overcome compliance and bioavailability challenges – and tackle controlled release in novel ways – transdermal drug delivery has presented itself as a rising star. Here, we speak with some of the companies and researchers riding the disruptive wave of innovation.
1 min read
February 26, 2016
Drug delivery by inhalation promises convenience and speed in many applications from the emergency room to home-based self-administration. But to succeed, the interactions between formulation, device and metering mechanism must be perfectly balanced with human factors. These challenges are a source of fascination for those looking to deliver drugs less invasively.
1 min read
February 26, 2016
Sitting Down With... Brian Overstreet, President at Advera Health Analytics, USA.
1 min read
February 26, 2016
In the US, whistle blowers who help uncover illegal offlabel promotion are usually awarded 15-25 percent of any recovered damages. Does incentivizing informants deter off-label drug marketing – and should other countries follow suit?
1 min read
February 25, 2016
The combination of genomic profiling and high-tech targeted drug delivery is opening up a new front in the fight against cancer.
1 min read
February 24, 2016
Demonstrating the stability of drug formulations over a range of times and environmental conditions is an essential aspect of drug development. But what exactly should be monitored – and how often?
1 min read
False
False